Zhitong Finance App learned that Moderna Inc. (MRNA.US) and MRK.US (MRK.US) announced that their personalized cancer vaccine successfully reduced the risk of melanoma recurrence in a large-scale late-stage trial, marking an important milestone in cancer therapy based on mRNA technology. The trial reached the main end — data showed that the vaccine in combination with MSD's immunization drug Keytruda can reduce the recurrence rate of melanoma compared to using Keytruda alone. The two companies said in a statement on Wednesday that the study simultaneously reached a critical secondary end, which is to prove that the vaccine helps prevent the spread of tumors to other parts of the body.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.